Targeting the tumour microenvironment in ovarian cancer

被引:92
作者
Hansen, Jean M. [1 ]
Coleman, Robert L. [1 ]
Sood, Anil K. [1 ,2 ,3 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, 1155 Pressler St, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, 1155 Pressler St, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNA, 1155 Pressler St, Houston, TX 77030 USA
关键词
Ovarian cancer; Tumour microenvironment; LYMPHOCYTE-ASSOCIATED ANTIGEN-4; CD8(+) T-LYMPHOCYTES; EPITHELIAL OVARIAN; INFILTRATING LYMPHOCYTES; MAINTENANCE THERAPY; RECURRENT OVARIAN; MYELOID CELLS; OPEN-LABEL; PHASE-II; MACROPHAGE POLARIZATION;
D O I
10.1016/j.ejca.2015.12.016
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The study of cancer initiation, growth, and metastasis has traditionally been focused on cancer cells, and the view that they proliferate due to uncontrolled growth signalling owing to genetic derangements. However, uncontrolled growth in tumours cannot be explained solely by aberrations in cancer cells themselves. To fully understand the biological behaviour of tumours, it is essential to understand the microenvironment in which cancer cells exist, and how they manipulate the surrounding stroma to promote the malignant phenotype. Ovarian cancer is the leading cause of death from gynaecologic cancer worldwide. The majority of patients will have objective responses to standard tumour debulking surgery and platinum-taxane doublet chemotherapy, but most will experience disease recurrence and chemotherapy resistance. As such, a great deal of effort has been put forth to develop therapies that target the tumour microenvironment in ovarian cancer. Herein, we review the key components of the tumour microenvironment as they pertain to this disease, outline targeting opportunities and supporting evidence thus far, and discuss resistance to therapy. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:131 / 143
页数:13
相关论文
共 153 条
[1]   PD-L1 on Tumor Cells Is Induced in Ascites and Promotes Peritoneal Dissemination of Ovarian Cancer through CTL Dysfunction [J].
Abiko, Kaoru ;
Mandai, Masaki ;
Hamanishi, Junzo ;
Yoshioka, Yumiko ;
Matsumura, Noriomi ;
Baba, Tsukasa ;
Yamaguchi, Ken ;
Murakami, Ryusuke ;
Yamamoto, Ayaka ;
Kharma, Budiman ;
Kosaka, Kenzo ;
Konishi, Ikuo .
CLINICAL CANCER RESEARCH, 2013, 19 (06) :1363-1374
[2]   Intraepithelial T Cells and Tumor Proliferation [J].
Adams, Sarah F. ;
Levine, Douglas A. ;
Cadungog, Mark G. ;
Hammond, Rachel ;
Facciabene, Andrea ;
Olvera, Narciso ;
Rubin, Stephen C. ;
Boyd, Jeff ;
Gimotty, Phyllis A. ;
Coukos, George .
CANCER, 2009, 115 (13) :2891-2902
[3]   OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [J].
Aghajanian, Carol ;
Blank, Stephanie V. ;
Goff, Barbara A. ;
Judson, Patricia L. ;
Teneriello, Michael G. ;
Husain, Amreen ;
Sovak, Mika A. ;
Yi, Jing ;
Nycum, Lawrence R. .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) :2039-2045
[4]   The inflammatory micro-environment in tumor progression: The role of tumor-associated macrophages [J].
Allavena, Paola ;
Sica, Antonio ;
Solinas, Graziella ;
Porta, Chiara ;
Mantovani, Alberto .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2008, 66 (01) :1-9
[5]  
[Anonymous], CA CANC J CLIN
[6]  
[Anonymous], ESMO
[7]  
[Anonymous], J CLIN ONCOL S
[8]  
[Anonymous], J CLIN ONCOL S
[9]  
[Anonymous], CANC MICROENVIRON
[10]   Smoldering and polarized inflammation in the initiation and promotion of malignant disease [J].
Balkwill, F ;
Charles, KA ;
Mantovani, A .
CANCER CELL, 2005, 7 (03) :211-217